General Atlantic
General Atlantic, established in 1980, is a global growth equity firm headquartered in New York, with additional offices across North America, Europe, Asia, and Latin America. The firm specializes in making large minority investments in growth-stage companies, focusing on sectors such as technology, consumer, financial services, and healthcare. General Atlantic employs a collaborative approach, combining sector-specific expertise, a long-term investment horizon, and a deep understanding of growth drivers to partner with exceptional management teams and build market-leading businesses worldwide.
Top Stages
Gabriel Caillaux
Co-President, Managing Director, Head of Climate, Head of Business EMEA and Member of the Executive, Investment and Portfolio Committees
Martin Escobari
Co-President, Managing Director, Head of Global Growth Equity, Chairman of the Investment Committee and Member of the Portfolio Committee
Anton Levy
Co-President, Managing Director, Member of the Investment Committee and Chairman of Global Technology Group
Sandeep Naik
Managing Director, Member of the Management Committee and Head of Business, India and Southeast Asia
Graves Tompkins
Managing Director, COO and Member of the Executive Committee and Investment Committee for GA Credit
Robbert Vorhoff
Managing Director, Member of the Management and Investment Committees and Global Head of Healthcare Sector
Past deals in Pennsylvania
Immunocore
Post in 2022
Immunocore Limited is a biotechnology company based in Abingdon, United Kingdom, with an additional office in Conshohocken. Founded in 1999, the company focuses on the discovery and development of innovative T cell receptor-based therapeutics aimed at addressing significant unmet medical needs in cancer, viral diseases, and autoimmune diseases. Immunocore specializes in engineering T cell receptors (TCRs) and linking them to antibody fragments, which has led to the development of its lead product candidate, IMCgp100, currently undergoing clinical trials for metastatic melanoma. The company's proprietary TCR technology platform is validated and designed for efficient manufacturing, supporting both clinical and commercial supply. Immunocore was previously known as Avidex Limited before adopting its current name in 2008.
Duolingo
Series H in 2020
Duolingo, Inc. is a language-learning platform founded in 2011 and headquartered in Pittsburgh, Pennsylvania. The company offers a wide array of educational resources, including 98 courses across nearly 40 languages, accessible for free or through a premium subscription model. With around 30 million active users, Duolingo has become a leading educational app globally, known for its engaging and gamified learning experience. Its offerings include the Duolingo Language Learning App, Super Duolingo, and the Duolingo English Test, which provides AI-driven language assessments. Additionally, Duolingo for Schools enables teachers to monitor their students' progress. The company's technology leverages advanced data analytics and artificial intelligence to enhance the learning process, while its revenue is primarily generated through subscriptions, in-app purchases, and business services.
Duolingo
Series G in 2020
Duolingo, Inc. is a language-learning platform founded in 2011 and headquartered in Pittsburgh, Pennsylvania. The company offers a wide array of educational resources, including 98 courses across nearly 40 languages, accessible for free or through a premium subscription model. With around 30 million active users, Duolingo has become a leading educational app globally, known for its engaging and gamified learning experience. Its offerings include the Duolingo Language Learning App, Super Duolingo, and the Duolingo English Test, which provides AI-driven language assessments. Additionally, Duolingo for Schools enables teachers to monitor their students' progress. The company's technology leverages advanced data analytics and artificial intelligence to enhance the learning process, while its revenue is primarily generated through subscriptions, in-app purchases, and business services.
Immunocore
Series B in 2020
Immunocore Limited is a biotechnology company based in Abingdon, United Kingdom, with an additional office in Conshohocken. Founded in 1999, the company focuses on the discovery and development of innovative T cell receptor-based therapeutics aimed at addressing significant unmet medical needs in cancer, viral diseases, and autoimmune diseases. Immunocore specializes in engineering T cell receptors (TCRs) and linking them to antibody fragments, which has led to the development of its lead product candidate, IMCgp100, currently undergoing clinical trials for metastatic melanoma. The company's proprietary TCR technology platform is validated and designed for efficient manufacturing, supporting both clinical and commercial supply. Immunocore was previously known as Avidex Limited before adopting its current name in 2008.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.